<DOC>
	<DOCNO>NCT00704925</DOCNO>
	<brief_summary>A new drug call 3,4-Diaminopyridine ( 3,4-DAP ) currently investigation treatment symptom Lambert-Eaton Myasthenic Syndrome ( LEMS ) . This expand access trial , mean although data study collect report US Food Drug Administration ( FDA ) drug manufacturer , formal study drug LEMS . If decide volunteer , evaluate neurologist determine eligibility receive 3 , 4-DAP review medical history , medication regimen ( medication take ) neurological examination . If female child-bearing potential , serum pregnancy test do ensure pregnant . Once determined treatment appropriate care , begin take 3 , 4 DAP mouth slowly increase dos . Treatment begin 5mg three time day , clinically need , tolerate . You monitor strength side effect routine clinic visit initial interval month , increase interval every 6 month permit . Blood drawn ( approximately 1 tablespoon ) every clinic visit often investigator deems necessary ass liver/kidney function blood count . You EKG ( test see heart function ) first study visit , 6 month take 3,4 DAP every 2 year . Treatment continue indefinitely good clinical response achieve . This study plan last indefinitely . The dosage 3 , 4DAP individually adjust . The usual range 10-15 mg 3-4 time per day full effect increase 50 % every two week 10-15 mg three six time day , need tolerate . Dosages full effect level provide additional benefit use . 3 , 4 DAP convulsant ( cause seizure ) . A total 100 mg/day maximum dosage allow .</brief_summary>
	<brief_title>Treatment Lambert-Eaton Syndrome With 3,4 DAP</brief_title>
	<detailed_description>Patients clinically-confirmed LEMS receive 3 , 4-DAP mouth slowly increase dos . Treatment begin 5 mg , three time day increase 50 % every two week 10-15 mg , three six time day , clinically need , tolerate . Patients monitor strength side effect via routine out-patient clinic visit initial interval 1 month , increase interval 6 month permit . Results treatment adverse event report FDA . Treatment continue indefinitely good clinical response achieve side effect tolerable .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Be 18 year old , diagnose LEMS If female , negative pregnancy test premenopausal , willing practice effective form birth control study . Is known sensitivity 3 , 4 DAP Has history past current seizure Has history past current severe asthma Is believe investigator unable comply protocol Unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lambert Eaton Myasthenic Syndrome</keyword>
	<keyword>3,4 DAP</keyword>
	<keyword>3,4 Diaminopyridine</keyword>
</DOC>